Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 1 shares, an increase of ∞ from the May 31st total of 0 shares. Based on an average daily volume of 1,105 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.
Starpharma Stock Up 1.0%
Shares of SPHRY traded up $0.04 during trading hours on Tuesday, reaching $4.72. 4,256 shares of the company traded hands, compared to its average volume of 2,162. The stock’s fifty day moving average is $4.92 and its 200 day moving average is $3.63. Starpharma has a 1-year low of $0.55 and a 1-year high of $5.70.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Read More
- Five stocks we like better than Starpharma
- The Quantum Bubble Is Real Enough to Take Seriously
- Why Wall Street Still Sees Massive Upside for AeroVironment Stock
- Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying
- Volkswagen’s 16-Year Low Masks a Massive Margin Engine
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
